ProCE Banner Activity

KEYNOTE-023: Pembrolizumab + Len/Dex in R/R MM

Slideset Download
Conference Coverage
Early results with pembrolizumab plus lenalidomide/dexamethasone show promising efficacy and acceptable safety profile in a heavily pretreated population of R/R MM.

Released: December 10, 2015

Expiration: December 08, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen